prognostic signature
Agendia, Paige Partner to Codevelop New Assays Using MammaPrint, BluePrint Signatures
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
Tiziana Life Sciences to Spin Off StemPrintER Asset Into Separate Company
The company, which originally announced plans for a possible spin off in June, will hold a shareholder meeting to vote on the details in October.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.
OncoCyte to Acquire Razor Genomics
OncoCyte believes Razor's CLIA-validated lung cancer prognostic test will complement its in-development DetermaVu lung cancer detection assay.